Skip to main content


Fig. 1 | BMC Cancer

Fig. 1

From: Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer

Fig. 1

Representative immunostaining of UC tissue for CD44v9 in patients with CD44v9 densities of 0%, 10%, 30%, and 60%. In CD44v9-positive tumors, CD44v9 was expressed in the epithelium of tumor glands with a heterogeneous expression pattern. At 400× magnification, the expression of CD44v9 was detected along the cell membrane. The bar indicates 200 μm

Back to article page